Comparative manufacture and cell-based delivery
of antiretroviral nanoformulations by Balkundi, Shantanu et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Papers from the Nebraska Center for Biotechnology Biotechnology, Center for
2011
Comparative manufacture and cell-based delivery
of antiretroviral nanoformulations
Shantanu Balkundi
University of Nebraska Medical Center
Ari S. Nowacek
University of Nebraska Medical Center
Ram S. Veerubhotla
University of Nebraska Medical Center
Han Chen
University of Nebraska - Lincoln
Andrea Martinez-Skinner
University of Nebraska Medical Center
See next page for additional authors
Follow this and additional works at: https://digitalcommons.unl.edu/biotechpapers
Part of the Biotechnology Commons, and the Molecular, Cellular, and Tissue Engineering
Commons
This Article is brought to you for free and open access by the Biotechnology, Center for at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Papers from the Nebraska Center for Biotechnology by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.
Balkundi, Shantanu; Nowacek, Ari S.; Veerubhotla, Ram S.; Chen, Han; Martinez-Skinner, Andrea; Roy, Upal; Mosley, R. Lee;
Kanmogne, Georgette; Liu, Xinming; Kabanov, Alexander V.; Bronich, Tatiana; McMillan, JoEllyn; and Gendelman, Howard E.,
"Comparative manufacture and cell-based delivery of antiretroviral nanoformulations" (2011). Papers from the Nebraska Center for
Biotechnology. 23.
https://digitalcommons.unl.edu/biotechpapers/23
Authors
Shantanu Balkundi, Ari S. Nowacek, Ram S. Veerubhotla, Han Chen, Andrea Martinez-Skinner, Upal Roy, R.
Lee Mosley, Georgette Kanmogne, Xinming Liu, Alexander V. Kabanov, Tatiana Bronich, JoEllyn McMillan,
and Howard E. Gendelman
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/biotechpapers/23
© 2011 Balkundi et al, publisher and licensee Dove Medical Press Ltd.  This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 3393–3404
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
3393
O r I g I N A L  r e s e A r c h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S27830
comparative manufacture and cell-based delivery 
of antiretroviral nanoformulations
shantanu Balkundi1
Ari s Nowacek1
ram s Veerubhotla1
han chen2
Andrea Martinez-skinner1
Upal roy1
r Lee Mosley1,3
georgette Kanmogne1
Xinming Liu1,3,4
Alexander V Kabanov3,4
Tatiana Bronich3,4
Joellyn McMillan1
howard e gendelman1,3
1Department of Pharmacology 
and experimental Neuroscience, 
University of Nebraska Medical 
center, Omaha, Ne, UsA; 2center  
for Biotechnology, University  
of Nebraska-Lincoln, Lincoln, Ne, 
UsA; 3center for Drug Delivery  
and Nanomedicine, University  
of Nebraska Medical center,  
Omaha, Ne, UsA; 4Department  
of Pharmaceutical sciences, college  
of Pharmacy, University of Nebraska 
Medical center, Omaha, Ne, UsA
correspondence: howard e gendelman 
Department of Pharmacology and 
experimental Neuroscience, 985880 
Nebraska Medical center Omaha,  
Ne 68198-5880, UsA 
Tel +1 402 559 8920 
Fax +1 402 559 3744 
email hegendel@unmc.edu
Abstract: Nanoformulations of crystalline indinavir, ritonavir, atazanavir, and efavirenz were 
manufactured by wet milling, homogenization or sonication with a variety of excipients. The 
chemical, biological, immune, virological, and toxicological properties of these formulations 
were compared using an established monocyte-derived macrophage scoring indicator system. 
Measurements of drug uptake, retention, release, and antiretroviral activity demonstrated 
 differences amongst preparation methods. Interestingly, for drug cell targeting and antiretroviral 
responses the most significant difference among the particles was the drug itself. We posit that 
the choice of drug and formulation composition may ultimately affect clinical utility.
Keywords: human immunodeficiency virus type one, nanotoxicology, monocyte-derived 
 macrophage, nanoformulated antiretroviral therapy, manufacturing techniques
Introduction
Antiretroviral therapy (ART) has profoundly reduced disease morbidity and  mortality 
among human immunodeficiency virus (HIV) infected individuals worldwide.1–5 
However, the short half-life of the drugs necessitates multiple daily dosing sched-
ules limiting both access and compliance. Moreover, failure of ART penetration into 
sanctuaries of persistent viral replication including the lymphoreticular and central 
nervous systems, and a range of secondary drug-induced toxicities further highlight 
the limitations of chronic drug treatment regimens.6–10 One approach to address 
such limitations is through long-acting antiretroviral drug nanoformulations with 
half-lives measured in week(s) rather than hours. To this end, improvements in drug 
 pharmacodynamics were described for ART nanoformulations (nanoART).4,11,12 Prior 
works demonstrated that such nanoART could be carried in monocyte-macrophages 
and reach viral sanctuaries.11–15 These studies also showed that size, shape, and 
charge of crystalline indinavir (IDV), ritonavir (RTV), atazanavir (ATV), and efa-
virenz (EFV) affect uptake, release, cytotoxicities, and antiretroviral responses.11,15–17 
However, absent from prior investigations was an analysis of the method of particle 
manufacture.
Crystalline nanoformulations11,16,18–24 prepared by sonication, wet milling and 
high-pressure homogenization differ in how surfactant-encapsulated drug crystals 
are produced. Wet milling produces particles by fractionating the surfactant-coated 
drug crystals to smaller sizes through impaction with micron-sized ceramic/zirconium 
beads.24–26 Homogenization elicits particle suspensions by passing surfactant-coated 
crystals through a narrow bore under high pressure (1500–20,000 psi).13,18,23  Sonication 
results in spherical poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles (NP), 
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in which the drug is dissolved in a polymer solution, then 
agitated by ultrasonication to obtain individual nanosized 
droplets.21,27,28 Such techniques can also produce unexpected 
findings in regard to particle integrity and its effects on the 
drug-carrier target cell. In addition, micelles can also be used 
as nanocarriers. However, these particles are smaller in size 
than the crystalline formulations and drug loading is much 
more limited. Different methods of nanoART construction 
can dramatically alter the particle’s physical properties 
and how they interact with carrier cells; thus, production 
methods can affect the ultimate translation of the final clini-
cal formulations.
Materials and methods
Preparation and characterization  
of nanoArT
RTV and EFV were obtained in the free base form from 
Shengda Pharmaceutical Co (Zhejiang, China) and Hetero 
Labs, Ltd (Hyderabad, India). The sulfate forms of IDV and 
ATV were purchased from Longshem Co (Shanghai, China) 
and Gyma Laboratories of America Inc (Westbury, NY), 
respectively. The free bases of IDV and ATV were made 
using a 1 N NaOH solution. The surfactants used in this 
study were: poloxamer-188 (P188; Sigma-Aldrich, St Louis, 
MO), 1,2-distearoyl-phosphatidylethanolamine-methyl-
polyethyleneglycol conjugate-2000 (mPEG
2000
DSPE) (Gen-
zyme Pharmaceuticals LLC, Cambridge, MA), and sodium 
dodecyl sulfate (SDS) (Bio-Rad Laboratories, Hercules, 
CA). These were suspended in 10 mM HEPES, pH 7.8, and 
free base drug was added (0.6% by weight). Combinations 
of drug and surfactant were (1) ATV in 0.5% P188; (2) IDV 
in 0.5% P188 and 0.5% SDS; (3) RTV or EFV in 0.3% P188 
and 0.1% mPEG
2000
DSPE. A homogeneous dispersion was 
formed by agitation with an Ultraturrax T-18 rotor-stator 
mixer (IKA® Works Inc, Wilmington, NC). For preparation 
of nanosuspensions by wet milling, mixtures were transferred 
to a NETZSCH MicroSeries Wet Mill (NETZSCH Premier 
Technologies, LLC, Exton, PA) with 50 mL of 0.8 mm grind-
ing media (zirconium ceramic beads, Saint-Gobain ZirPro, 
La Pontet, France). The sample was milled for 30 minutes to 
1 hour at speeds ranging from 600 to 4320 rpm until desired 
particle size was achieved.11,16 For preparation of suspensions 
by homogenization, mixtures were transferred to an Avestin 
C5 high-pressure homogenizer (Avestin Inc, Ottawa, ON) 
and extruded at 20,000 pounds per square inch for ∼30 
passes or until the desired particle size was attained.15,16 
Particle size, polydispersity (PDI), and surface charge (zeta 
potential) were determined by dynamic light scattering (DLS) 
using a Malvern Zetasizer Nano Series Nano-ZS (Malvern 
Instruments Inc, Westborough, MA). A Hitachi S4700 Field-
Emission Scanning Electron Microscope (Hitachi High 
Technologies America Inc, Schaumburg, IL) was used to 
evaluate particle morphology and validate DLS tested particle 
size. After the desired particle size was achieved, samples 
were centrifuged at 10,000 × g for 30 minutes at 4°C. The 
resulting pellet was resuspended in surfactant solution 
containing 9.25% sucrose to adjust tonicity. Drug concentra-
tion in the final suspension was determined using reverse-
phase high-performance liquid chromatography (RP-HPLC) 
as previously described.15
For manufacturing NP using sonication, 6 g of PLGA, 
(RESOMER RG752H; Sigma-Aldrich) was added to 50 mL 
dichloromethane (HPLC-grade) and mixed until complete 
dissolution. Drug crystals (1.25 g) were added to the dichlo-
romethane/PLGA solution and mixed to obtain complete 
dissolution. This solution was added to a 1% polyvinyl alco-
hol (PVA; Sigma-Aldrich) surfactant solution cooled in an 
ice bath, and then sonicated using a Cole Parmer Ultrasonic 
processor (Vernon Hills, IL) at 50% amplitude for 10 min-
utes. Particle size was determined by dynamic light scatter-
ing using a Zetasizer. The sonication time was increased at 
2-minute intervals up to a maximum of 16 minutes total if 
the particle size was greater than 1.5 µm. The samples were 
characterized by light microscopy (20× magnification). 
The remaining suspension was vortexed and mixed at an 
adequate speed overnight at room temperature, then col-
lected after 24 hours and centrifuged step-wise at 8100 × g 
for 20 minutes at 5°C. After decanting the supernatant, the 
pellet was resuspended in 75 mL of filtered, reverse osmosis 
(RO) water and the samples centrifuged again at 8100 × g 
for 20 minutes at 5°C. The pellet was resuspended in 1% 
mannitol (Sigma-Aldrich) in RO water for lyophilization. 
The particle size was again measured using a Zetasizer and 
drug concentration determined by RP-HPLC.16
human monocyte isolation  
and cultivation
Human monocytes were obtained by leukapheresis from 
HIV-1 and hepatitis B seronegative donors and purified 
by counter-current centrifugal elutriation. Cell purity was 
greater than 96% as determined by immunolabeling with 
anti-CD68 (clone KP-1) from Wright-stained cytospins. 
Monocytes were cultured in Dulbecco’s Modified Eagles 
Medium (DMEM) supplemented with 10% heat-inactivated 
human serum, 1% glutamine, 50 µg/mL gentamicin, 
10 µg/mL ciprofloxacin, and 1000 U/mL recombinant 
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human macrophage-colony stimulating factor (MCSF) (a 
generous gift from Pfizer Inc, Cambridge, MA) at a cell 
density of 1 × 106 cells/mL at 37°C in a 5% CO
2
 humidified 
atmosphere. Monocytes differentiated into monocyte-derived 
macrophages (MDM) after 7 days of culture.29
electron microscopy
For scanning electron microscopy (SEM) of the nanopar-
ticles, 10 µL of nanosuspension was diluted in 1.5 mL of 
0.2 µm-filtered double distilled water. The diluted suspen-
sion was mixed, and a 50 µL aliquot was transferred to a 
filtration apparatus (Swinnex 13 polypropylene filter holder, 
Millipore, Billerica, MA) assembled with a 0.2 µm pre-wetted 
polycarbonate filter membrane (Nuclepore Track-Etched, 
Whatman International Ltd, Kent, ME). The entire solu-
tion volume was pulled through the filtration membrane by 
vacuum. The membrane was washed with 500 µL of filtered 
double-distilled water. The membrane was allowed to dry for 
24 hours, fixed to an aluminum pin stub using double stick 
conductive carbon tape, and sputter coated with palladium 
(EMITECH K575X; Quorum Technologies, Ashford, Kent, 
UK). The lyophilized PLGA NP were fixed to the double 
stick conductive carbon tape surface and sputter coated 
with palladium before imaging. The samples were affixed 
to the specimen stub and imaged using a Hitachi S4700 
Field-Emission Scanning Electron Microscope (Hitachi High 
Technologies America Inc, Schaumburg, IL).
NanoArT uptake and release kinetics
MDM uptake, retention, and release of nanoART were deter-
mined as previously described.15 MDM were incubated with 
100 µM nanoART and cell uptake determined over an 8-hour 
period. Adherent MDM were washed three times with phos-
phate buffered saline (PBS) and scraped into 1 mL PBS. Cells 
were pelleted by centrifugation at 950 × g for 10 minutes 
at 4°C and the supernatant was removed. Cell pellets were 
resuspended in 200 µL of HPLC-grade methanol, sonicated, 
and centrifuged at 20,000 × g for 10 minutes at 4°C. The 
methanol extract was stored at –80°C until drug analysis. 
For determination of cell retention and release of nanoART, 
MDM were exposed to 100 µM nanoART for 8 hours, washed 
three times with PBS, and fresh medium added. MDM were 
cultured for up to 15 days with half medium exchanges every 
other day for all treatment assays. On days 1, 5, 10, and 15 
following nanoART treatment, MDM were collected and 
methanol extracts prepared. Replicate media samples were 
collected at each time point. Both cell extract and media 
samples were stored at –80°C until processed and analyzed 
for drug by HPLC as previously described.15 Duplicate 
20 µL injections of processed cells or media were analyzed 
by RP-HPLC using a YMC-Pack Octyl C8 column (Waters 
Inc, Milford, MA) with a C8 guard cartridge. Analytes were 
eluted using a mobile phase of 48% acetonitrile/52% 25 mM 
KH
2
PO
4
, pH 4.15, at a flow rate of 0.4 mL/minute and were 
detected by UV detection at 212 nm. Drug levels were quan-
titated by comparison of peak area to a standard curve of free 
drug (0.025–100 µg/mL) in methanol.
hIV-1 infection
MDM were treated with 100 µM nanoART for 8 hours, 
washed to remove excess drug, then given fresh medium 
without drug. At days 1, 5, 10, and 15 following nano-
ART treatment, the cells were infected with HIV-1
ADA
 at 
a multiplicity of infection (MOI) of 0.01 infectious viral 
particles/cell.29 Following 24-hours of infection, virus was 
washed away and medium was replaced with fresh virus-
free medium. Cells were cultured for an additional 10 days 
with half medium exchanges every other day. At this time, 
medium samples were collected for measurement of reverse 
transcriptase (RT) activity and cells were fixed in 4% para-
formaldehyde (PFA) for determination of HIV-1p24 antigen 
expression.
Measurement of rT activity
RT activity in cell medium samples was determined as pre-
viously described.12 Cell supernatant samples (10 µL) were 
mixed with 10 µL of 100 mM Tris-HCl (pH 7.9), 300 mM 
KCl, 10 mM DTT, and 0.1% nonyl phenoxylpolyethoxyl-
ethanol-40 (NP-40) in a 96-well plate. The samples were 
incubated at 37°C for 15 minutes. Twenty-five microliters of a 
solution containing 50 mM Tris-HCl (pH 7.9), 150 mM KCl, 
5 mM DTT, 15 mM MgCl
2
, 0.05% NP-40, 10 µg/mL poly(A), 
0.250 U/mL oligo d(T),12–18 and 10 µCi/mL 3H-TTP was 
then added to each well and incubated at 37°C for 18 hours. 
Following incubation, 50 µL of ice-cold 10% trichloroacetic 
acid was added to each well, and the well contents were 
harvested onto glass fiber filters and assessed for 3H-TTP 
incorporation by β-scintillation spectroscopy.30
hIV-1p24 antigen immunostaining
HIV-1p24 antigen staining was determined in PFA-fixed cells 
as previously described.12 Mouse monoclonal antibodies to 
HIV-1 p24 (1:100, Dako, Carpinteria, CA) were used to detect 
HIV-1 infected cells. Binding of p24 antibody was detected 
using Dako EnVision+ System-HRP labeled polymer anti-
mouse secondary antibody and diaminobenzidine staining. 
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Images were acquired using a Nikon TE300 microscope with 
a 20× objective (Nikon, Tokyo, Japan).
cytotoxicity
For determination of cytotoxicity, MDM were cultured at a 
concentration of 6.25 × 105 cells/mL and treated with nano-
formulations of IDV, RTV, or EFV at 0.1 mM for 12 hours 
at 37°C in 5% CO
2
. Following loading of each nanoformula-
tion, cells were washed with serum-free culture medium to 
remove excess NP and cytotoxicity assessed over the subse-
quent 24 hours using the alamarBlueTM assay (AbD Serotec, 
Raleigh, NC) according to the manufacturer’s instructions.
statistical analyses
Data analyses were carried out using Prism (GraphPad 
Software Inc, La Jolla, CA). Significant differences in 
cytotoxicity response were determined by one-way ANOVA 
followed by Bonferroni’s multiple comparisons test. P values 
for significance are indicated.
Results
characterization
Nanoformulations of antiretroviral drugs were prepared 
by wet milling, homogenization, and sonication. Dynamic 
light scattering was used to determine particle size, poly-
dispersity index (PDI), and surface charge (zeta potential). 
Wet milled and homogenized formulations for each drug 
contained identical surfactants and were similar in size and 
charge (Table 1). The IDV nanoformulations, M1004 and 
H1004, were the most diverse with sizes of 252 and 418 nm 
and charges of –40.6 and –15.1 mV, respectively, for those 
milled and homogenized particles. P1001 was 366.6 nm in 
size, smaller than the nanocrystals, but had a PDI of 0.451. 
The charge of P1001 (–9.57 mV) was lower than M1004 
and H1004. The PDI of the nanocrystal formulations ranged 
from 0.152 for M2006 to 0.295 for H4002, indicating a size 
diversity of the NP. The NP formed by sonication of ATV, 
RTV, and EFV were consistent in size and PDI. 
Scanning electron microscopy (SEM) at 15,000× 
magnif ication was used to visualize nanoART mor-
phologies, This approach showed that the IDV crystals 
appeared as short rods with rough edges (Figure 1). The 
ATV crystals formed longer thin rods with smooth edges. 
RTV nanocrystals formed short thick rods. EFV particles 
were ellipsoid. Overall, the NP manufactured with milling 
had rougher edges than those made by homogenization. 
All NP manufactured with sonication using PLGA were 
spherical.
NanoArT uptake by MDM
MDM uptake of wet milled and homogenized nanoformula-
tions was compared for each drug during an 8-hour time inter-
val (Figure 2). Previous studies have shown that levels of drug 
in MDM exposed to crystalline nanoformulations of IDV, 
RTV, ATV, or EFV are more than 90% of maximum levels 
by 8 hours.12,15 At 2, 4, and 8 hours, MDM uptake of homog-
enized nanoformulations of IDV and EFV was greater than 
observed with wet milled formulations. At 8 hours, IDV and 
EFV levels in MDM were 1.4-fold higher with homogenized 
compared to wet milled formulations. In contrast, uptake 
of H2006 and H3001 was less than for M2006 and M3001, 
respectively. At 8 hours, drug levels of RTV in MDM were 
11.3 vs 9.3 µg/106 cells for M2006 and H2006, respectively. 
Similarly, levels of ATV were 36.6 vs 29.6 µg/106 cells for 
Table 1 Physicochemical characteristics of nanoformulations of antiretroviral drugs
Drug Formulation designation Surfactant Size (nm)a PDIb Zeta potential (mV)
Indinavir IDV-M1004 P188, sDs 252 0.286 –40.58
IDV-h1004 P188, sDs 418 0.239 –15.09
IDV-P1001 PLgA, PVA 367 0.451 –9.57
ritonavir rTV-M2006 P188, mPeg2000DsPe 374 0.152 –30.11
rTV-h2006 P188, mPeg2000DsPe 405 0.220 –28.79
rTV-P2001 PLgA, PVA 302 0.22 –26.10
Atazanavir ATV-M3001 P188 281 0.288 –15.31
ATV-h3001 P188 314 0.200 –31.65
ATV-P3001 PLgA, PVA 270 0.148 –26.40
efavirenz eFV-M4002 P188, mPeg2000DsPe 325 0.281 –32.47
eFV-h4002 P188, mPeg2000DsPe 388 0.295 –24.43
eFV-P4001 PLgA, PVA 288 0.198 –31.00
Notes: aThe particle sizes; bpolydispersity indices (PDI) were determined by dynamic light scattering; the z-average diameters are presented.
Abbreviations: ATV, atazanavir; DsPe, 1,2-distearoyl-phosphatidyl-ethanolamine; eFV, efavirenz; IDV, indinavir; mPeg, methyl-polyethylene-glycol; P188, poloxamer 188; 
PLgA, poly(lactic-co-glycolic acid); PVA, polyvinylalcohol; rTV, ritonavir; sDs, sodium dodecyl sulfate. M, wet milled; P, PLgA; h, homogenized.
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M3001 and H3001, respectively. The uptake of P1001 was 
higher than M1004 and H1004 at 2 hours and ∼1.2 times 
lower than homogenized NP at 4 hours. Uptake of P3001 
was lower than for both M3001 and H3001. ATV concentra-
tion in cells after 8 hours (8.1 µg/106 cells) was 3- to 4-fold 
lower following P3001 treatment than that for homogenized 
or milled particles (29.6 and 36.6 µg/106 cells, respectively). 
P2001 was rapidly taken up over the first hour and at 8 hours 
was 6.6 µg/106 cells compared to 9.4 µg/106 cells and 
11.3 µg/106 cells for H2006 and M2006, respectively. For 
EFV, the uptake of P4001 was ∼2-fold lower than for M4001 
and H4001 and at 8 hours was 0.6 µg/106 cells vs 1.0 and 
1.5 µg/106 cells, for M4001 and H4001, respectively.
NanoArT retention and release by MDM
Retention profiles within cells were similar for wet milled, 
homogenized, and PLGA formulations of the four drugs 
(Figure 2). The cellular drug content for all IDV formula-
tions decreased by .85% over 24 hours and was undetect-
able by day 5. This was also observed for EFV formulations 
although limited drug levels were present at day 10. The 
concentration of the drug was lower at days 1 and 5 for P2001 
compared to M2006 and H2006. Drug levels retained with 
all ATV formulations was significantly higher than the oth-
ers manufactured using all three techniques. The amount of 
drug retained after 15 days was ∼10 µg/106 cells for M3001 
and H3001 and ∼2 µg/106 cells for P3001.
Drug
IDV
RTV
ATV
EFV
Wet milled Homogenized PLGA
Figure 1 scanning electron microscopy (seM) images of nanoArT morphology.
Notes: SEM analysis (magnification, 15,000×) of nanoformulated IDV, rTV, ATV, and eFV produced by homogenization, wet-milling, and sonication on top of a 0.2 µm 
polycarbonate filtration membrane. Scale bar equals 10 µm for IDV and 3 µm for rTV, ATV and eFV. Wet milling and homogenization show crystalline nanoparticles while 
sonicated formulations are seen as spherical nanoparticles.
Abbreviations: IDV, indinavir; rTV, ritonavir; ATV, atazanavir; eFV, efavirenz.
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Retention levels of IDV and EFV in MDM fell to less than 
10% of loading levels by 24 hours after medium exchanges, 
were minimal at 5 days, but were undetectable by 10 days. 
Levels of RTV fell 65%–70% during the first 24 hours after 
cell loading, were 15%–30% of loading levels at 5 days, 
and were undetectable by 10 days. The cell levels of P2001 
formulations were also reduced by 70% in the first 24 hours 
and were 10% of loading levels at 5 and 10 days, but were 
undetectable at day 15. Cellular levels of ATV dropped 70% 
during the first 24 hours then remained at 20% of loading 
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levels through 15 days. This observation is significant as ATV 
is a leading drug in the clinic.31,32
While initial medium levels (24 hour post-treatment) 
were variable between wet milled or homogenized and PLGA 
formulations, the rate of decline was similar for wet milled 
and homogenized formulations. Medium levels at day 1 were 
higher for H1004 than for M1004, but the rates of decline were 
similar for both formulations. RTV levels in the medium were 
also higher for H2006 than for M2006 at 1 day, but levels of 
both formulations only slightly declined over the next 5 days. 
By 10 days, medium levels were low to undetectable for either 
RTV formulation. Levels of ATV release were similar for both 
M3001 and H3001. Medium levels of ATV remained steady 
from 1 to 15 days. Medium levels of EFV were also higher 
for H4002 than for M4002 at 1 day. Similar to the profile seen 
for RTV, the medium levels of EFV only slightly declined 
over the next 5 days, but then fell to undetectable levels by 
10 days. For the PLGA formulations, there were sharp declines 
of drug release. The drug levels reduced by a total of more 
than 80% in 5 days and were undetectable at day 10 with the 
exception of P2001 at day 5. The medium level remained 
almost the same for P3001 over the first 5 days, was reduced 
by 50% at 10 days and was undetectable on day 15. P4001 
levels in media reduced by 80% by 5 days, an additional 10% 
by 10 days, and were undetectable by day 15.
NanoArT-induced antiretroviral activities
Antiretroviral efficacy was assessed by measuring RT activity 
and HIV-1p24 following one exposure of MDM to nanoART 
and serial-timed infections (1–15 days) with HIV-1
ADA
. Viral 
profiles were similar for milled, homogenized and PLGA 
formulations of each drug when determined by RT activity 
(Figure 3). All formulations, both crystalline and PLGA, sup-
pressed viral replication by .87% when viral challenge was 
made 1 day after nanoART treatment. This suppression was 
reduced for viral challenges at 5 to 15 days after nanoART 
treatment for IDV, RTV, and ATV. For IDV formulations, sup-
pression was reduced from 44% for H1004 on viral challenge 
day 5% to 23% and 21% on days 10 and 15, respectively. 
Suppression over time was similar for M1004, at 33% on 
day 5, declining to 28% on day 10, and reaching 21% on 
day 15. The viral suppression for P1001 was greater than for 
M1004 or H1004 and ranged from 74% at day 5 to 54% by 
day 15. For RTV formulations, the profiles were very similar 
for M2006 and H2006, with viral suppression greater than 
83% on day 5. Suppression was reduced to ,32% on day 10 
and by day 15 was only 24%. In contrast, P2006 suppression 
remained .67% for days 5, 10, and 15. For all ATV formu-
lations, viral suppression was .70% when challenged on 
days 5, 10, or 15 after nanoART was administered to the 
MDM. EFV formulations were the most effective at sup-
pressing viral replication. All EFV formulations suppressed 
viral expression by .87% on all challenge days including 
day 15. These results were mirrored by immunostaining of 
HIV-1p24 antigen (Figure 4). In general, a time-dependent 
increase in HIV-1p24 antigen was observed from challenge 
days 1 through 15. At all timepoints, immunostains of EFV 
nanoformulation-treated MDM administered prior to viral 
infection were similar to uninfected cells.
cytotoxicity tests
To determine whether uptake and retention of nanoformula-
tions would be detrimental to MDM, we evaluated cytotoxic-
ity of eight independent NP manufactured by two different 
methods, homogenization and wet milling, using the ala-
marBlueTM redox assay. These included four homogenized 
(two RTV, one ATV, and one EFV) and four wet milled (two 
RTV, one ATV, and one EFV) formulations. alamarBlueTM 
redox assay tests were performed on human MDM using 
each formulation administered at a dose of 0.1 mM.17 
Cytotoxicity was determined at 24 hours and demonstrated 
that homogenized RTV nanoformulations induced modest 
changes (15% decrease at 24 hours) in MDM viability com-
pared to control cells. For milled RTV nanoformulations, 
while M2006 induced no significant change in alamarBlueTM 
reduction compared to control cells at 24 hours, M2001 
significantly decreased MDM viability by 53% at 24 hours 
(Figure 5A). ATV nanoformulations did not significantly 
affect cell viability compared to control cells (Figure 5B), 
while EFV nanoformulations decreased cell viability by 
30%–67% (Figure 5C). Fluconazole nanoparticles manu-
factured in parallel as exipient controls showed no effect 
on MDM viability and function.17
Discussion
We prepared NP using poorly water-soluble antiretroviral 
drugs by wet milling, homogenization, and sonication, and 
studied differences in nanoART responses. We used a cell-
based screening approach to perform a direct comparison 
of nanoformulations of antiretroviral drugs produced by a 
variety of manufacturing techniques. We did this in order 
to assess which formulations could be further developed 
as long-acting injectables for animal and inevitably clinical 
studies. IDV-, RTV-, ATV-, and EFV-NP coated with the 
same excipients were compared for size, shape, and charge. 
The IDV wet milled and homogenized NP were diverse in 
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size. Indeed, their PDI values indicated that they were not 
homogeneous and hence yielded a wide range of particle 
sizes. While the excipient used for manufacturing IDV-
PLGA NP was different than that for the nanocrystals, all 
NP were similar in size and charge distributions regardless 
of formulation technique; however nanocrystals were more 
homogeneous than PLGA particles and IDV-PLGA NP did 
not have a significant charge. Our previous studies have 
shown that particles with a weak charge are taken up to a 
lesser extent by MDM than particles with a stronger charge 
(positive or negative).15 Wet milled IDV NP were more 
negatively charged than homogenized and PLGA particles. 
RTV NP manufactured using all three techniques were similar 
in size and charge. ATV- and EFV-PLGA particles were more 
homogeneous than the ATV and EFV nanocrystals. Other 
physical characteristics were similar.
The use of MDM as a vehicle for drug delivery supports 
the idea that the cells have a preference for uptake in regard 
to drug type. MDM uptake of ATV NP manufactured by wet 
milling and homogenization was significantly higher than for 
those NP made from the other three drugs. In addition, the 
milled and the homogenized particles were taken up better by 
MDM than their respective PLGA formulations. RTV-PLGA 
NP was one exception that exhibited a high initial drug uptake. 
Drug retention was notable in ATV formulations particularly 
for the nanocrystals. ATV is one of the leading protease 
inhibitors currently prescribed in the clinic.31,32 Daily doses 
of RTV, another protease inhibitor, are used to boost ATV 
levels, thus a sustained-release formulation containing both 
ATV and RTV would help simplify ART regimens.32 Our 
NP manufactured with RTV showed that MDM retained the 
drug for up to 10 days. This sustained-release profile can be 
used to our advantage since it is a significant improvement 
over the current oral dosage regimen that requires patients to 
take one single-tablet daily.33 We used the sustained release of 
ATV and RTV NP to assess the efficacy of nanosuspensions 
since optimal adherence to conventional oral dosing regimens 
remains a clinical problem. Oral administration of antiretroviral 
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Figure 3 comparison of antiretroviral effects of various formulations of IDV, rTV, ATV, and eFV as measured by reverse transcriptase (rT) activity.
Notes: Monocyte-derived macrophages (MDM) were treated with 100 µM of nanoparticles for 8 hours. MDM were infected with hIV-1ADA on days 1, 5, 10, and 15 
post-loading and cultured for 10 days after infection. Medium was removed and rT activity was measured by 3h-TTP incorporation. Data are normalized to activity in 
hIV-1 infected untreated cells cultured in parallel. Data represent mean ± seM for n = 4 determinations per treatment.
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drugs has low biodistribution and elicits sustained viral sanc-
tuaries that affect drug resistance.2,5 We reported previously 
that nanoformulations using macrophage-based drug delivery 
provide stable drug levels, and are able to reach viral sanctuar-
ies when administered ex vivo.14 The drug taken up by MDM 
is active for a period of weeks as opposed to the conventional 
non-nanoformulated drugs, which are metabolized quickly, 
requiring the patients to follow daily dosing schedules. With 
conventional antiretroviral drugs administered orally, it is 
unlikely that suitable drug concentrations could be achieved at 
A
Day
IDV RTV
M1004
1
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10
15
1
P1001 P2001 P3001
Control +HIV
Control +HIV
P4001Day
B
IDV RTV ATV EFV
5
10
15
H1004 M2006 H2006 M3001 H3001 M4002 H4002
ATV EFV
Figure 4 Antiretroviral efficacy of nanoART as determined by HIV-1p24 antigen staining.
Notes: Monocyte-derived macrophages (MDM) were loaded for 8 hours with IDV, rTV, ATV and eFV nanoparticles manufactured by (A) wet milling and homogenization or (B) 
sonication. MDM were infected with hIV-1ADA on days 1, 5, 10, and 15 post-loading and cultured for an additional 10 days. MDM were fixed and immunostained for expression 
of p24. Untreated, uninfected MDM served as negative controls (control), while MDM exposed to hIV-1ADA but not treated with nanoArT, served as positive controls (+hIV). 
expression of viral p24 antigen was visualized by DAB chromogen (brown). Images are representative of n = 4 determinations per treatment. (Magnification, 200×).
Abbreviations: IDV, indinavir; rTV, ritonavir; ATV, atazanavir; eFV, efavirenz.
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sites of HIV-infected tissues such as the brain or deep within 
the lymph nodes. NanoART has the potential to be effective in 
tissue sites where drug penetration by native drugs is limited. 
In this context, macrophages would carry drug-laden NP to 
tissue sites where conventional, oral drug administration could 
not reach. As noted MDM has potential advantages for ART 
delivery. One rests in the fact that antiretroviral efficacy may 
also be enhanced by subcellular delivery of ART into endo-
somal compartments where active viral replication ensues.34
The current studies suggest that all the manufacturing 
techniques would result in similar profiles for viral sup-
pression by nanoART. Amongst the protease inhibitors, 
ATV was the most efficacious as viral suppression values 
were maintained at ∼70% and higher with all formulations 
manufactured using homogenization, milling, and sonication. 
Although, the suppression values were reduced to 24% by 
day 15 for RTV nanocrystals, this was significant since RTV 
is shown to boost the effect of ATV and has been reported to 
be effective and well-tolerated in HIV patients.35 The PLGA 
NP, although having higher viral suppression values, were 
held as less effective since their uptake was lower, reducing 
the chances to develop a sustained-release profile required 
to increase the drug-dosing interval. While EFV NP viral 
suppression values were at 95% and above for wet milled 
and homogenized formulations and above 90% for PLGA 
NP, the maximum uptake achieved using EFV was below 
1.5 µg/106 cells. The significant suppression seen for EFV 
as compared to ATV and RTV is based on the known non-
nucleoside reverse transcriptase inhibition of antiretroviral 
replication.36 Nonetheless and although substantively effi-
cacious, EFV has been reported to have commonly shown 
central nervous system side effects as well as population dif-
ferences in pharmacokinetics.37 These comparisons of IDV-, 
ATV-, RTV-, and EFV-NP support the idea that MDM are a 
viable screening system that can be extended to applications 
of other drugs and infectious diseases.
Destache et al19 manufactured PLGA NP containing 
RTV, EFV, and lopinavir and reported concentration of anti-
retroviral drugs over a period of 28 days from NP incubated 
with peripheral blood mononuclear cells. The cellular drug 
level reported on day 4 for RTV was 2.5 µg and for EFV was 
10.6 µg; all formulations had drug concentrations $0.9 µg. 
The results suggested the use of PLGA NP for drug delivery 
using parenteral administration for prolonged release of drug. 
Since total drug loading of PLGA NP is ∼4%–5% (w/w), 
prolonged parenteral administration of PLGA NP would 
result in exposure to high levels of excipients. With regard 
to PLGA-EFV NP the high level of drug in cells could result 
from more EFV being encapsulated in the NP as compared to 
the others although equal quantities of each drug were used 
in making the formulations. Cell uptake assays performed 
in those studies also worked on the assumption that aliquots 
sampled had cell equivalents. All together, the physical 
characteristics of PLGA NP for drug uptake and retention 
were limited.
To further support the use of cell-mediated drug delivery, 
nanocrystalline particles were used for toxicity studies. The 
ATV nanoparticles produced by the different manufacturing 
techniques did not significantly affect MDM viability, whereas, 
EFV nanoparticles affected MDM viability regardless of the 
method of manufacture. However, the manufacturing method 
did affect RTV nanoformulation cytotoxicities. Comparison 
of RTV nanoparticles prepared by homogenization and wet 
milling showed that the P188-coated RTV particles produced 
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by wet milling induced more cytotoxicity than homogenized 
particles. Although wet milling and homogenization techniques 
produced NP that were similar in nature, the toxicity of the wet 
milled particles may be linked to the grinding media itself that 
contacts the drug and the excipient. The zirconium/ceramic 
media, although highly resistant to wear, has a tendency to 
break down over time because of the high milling speeds. This 
might contaminate the samples over time. Another possible 
source of contamination is wearing down of the metal screen 
that is used to prevent entry of the grinding media into the 
suspension during processing. Homogenization provided a 
non-contamination process, where no media is necessary to 
fractionate the drug particles. The homogenizer is controlled 
by a pneumatically-dynamic homogenizing valve with seals 
that are made of metal and do not use latex or rubber “O” rings. 
Any residual fluids after a complete cycle are removed from 
the instrument by blowing the system out with compressed 
air. This feature limits possible contaminants that could affect 
toxicity profiles.
We previously investigated the subcellular distribution 
of the drug particles in macrophages from the initial 
stage of cellular uptake to that of final release of the drug. 
NanoART proceeds through a sorting process into a recycling 
pathway after rapid clathrin-dependent internalization.34 
Consequently, NP are in recycling endosomal compartments 
where a significant component of the virus’ life cycle 
occurs.34,38,39 The data suggest that nanoART could enter 
the cell together with the virus and be located in identical 
subcellular destinations, further assisting in a targeted 
delivery to subcellular compartments. This could explain how 
nanoART are capable of suppressing HIV at low intracellular 
concentrations.11–13,15,20,34 Storage of the NP in recycling 
endosomes also helps avoid intracellular degradation and 
assists in the release of the NP at the cell surface. This method 
of particle trafficking may be analogous to HIV endocytic 
sorting, thus further assisting in restricting viral replication. 
After NP are recycled to the plasma membrane, they are 
intact and retain their antiretroviral properties. This strongly 
supports the role of MDM as “Trojan horses” for nanoART 
drug delivery and a mechanism for inhibiting viral replication 
at all sites of infection. These findings have established that 
macrophage-mediated drug delivery is a critical therapeutic 
option for an efficient and simplified drug regimen for the 
treatment of HIV.
Conclusion
NanoART have the potential to overcome the limitations in 
drug compliance, pharmacokinetics, and toxicities. We have 
shown that repackaging of clinically available antiretroviral 
medications into NP is a viable option for HIV treatment. 
We have also shown that a cell-based screening approach is 
an effective way to evaluate a wide variety of formulations. 
This will aid in the selection of superior performing formula-
tions for future studies of long-acting injectables designed to 
increase the drug dosing interval and thus improve patient 
compliance.
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